Study reveals significant discrepancies in the labeled and actual cannabidiol content in various commercial products, highlighting a major quality control issue.
Pfizer culls RSV treatment from ReViral acquisition
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS